Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedMar 07, 2026
DataAggregated Company Financials
Companies5
  • 7D-11.4%
  • 3M-21.9%
  • 1Y-10.4%
  • YTD-19.8%

Over the last 7 days, the Biotech industry has dropped 2.4%, driven by Genmab declining 3.2%. As for the longer term, the industry's performance has been flat for the past year. As for the next few years, earnings are forecast to decline by 2.9% per annum.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 07 Mar 2026DKK 137.5bDKK 40.1bDKK 15.0b5.8x9.2x3.4x
Mon, 02 Feb 2026DKK 169.6bDKK 40.3bDKK 18.9b6.1x9x4.2x
Wed, 31 Dec 2025DKK 173.2bDKK 40.5bDKK 18.9b6.1x9.1x4.3x
Fri, 28 Nov 2025DKK 177.1bDKK 40.8bDKK 19.1b5.9x9.3x4.3x
Sun, 26 Oct 2025DKK 169.9bDKK 39.0bDKK 16.8b13.3x10.1x4.4x
Tue, 23 Sep 2025DKK 161.9bDKK 38.7bDKK 16.7b12.7x9.7x4.2x
Thu, 21 Aug 2025DKK 142.8bDKK 38.7bDKK 16.7b10.8x8.6x3.7x
Sat, 19 Jul 2025DKK 128.1bDKK 27.1bDKK 7.4b11.4x17.4x4.7x
Mon, 16 Jun 2025DKK 138.2bDKK 27.2bDKK 7.4b11.6x18.7x5.1x
Wed, 14 May 2025DKK 121.4bDKK 28.0bDKK 7.9b9.7x15.4x4.3x
Fri, 11 Apr 2025DKK 119.6bDKK 27.3bDKK 7.7b10.7x15.6x4.4x
Sun, 09 Mar 2025DKK 156.9bDKK 27.3bDKK 7.7b13.3x20.4x5.7x
Tue, 04 Feb 2025DKK 158.5bDKK 26.0bDKK 4.7b15.9x33.8x6.1x
Thu, 02 Jan 2025DKK 160.9bDKK 26.0bDKK 4.7b16.7x34.3x6.2x
Sat, 30 Nov 2024DKK 164.4bDKK 26.0bDKK 4.7b17.1x35x6.3x
Mon, 28 Oct 2024DKK 179.0bDKK 25.5bDKK 5.5b21.3x32.7x7x
Wed, 25 Sep 2024DKK 181.4bDKK 25.5bDKK 5.5b22.1x33.1x7.1x
Fri, 23 Aug 2024DKK 200.7bDKK 26.1bDKK 5.7b21.2x35x7.7x
Sun, 21 Jul 2024DKK 195.0bDKK 24.8bDKK 5.6b18.2x34.6x7.9x
Tue, 18 Jun 2024DKK 169.0bDKK 24.8bDKK 5.6b16.9x30x6.8x
Thu, 16 May 2024DKK 188.1bDKK 25.2bDKK 6.2b16.7x30.5x7.5x
Sat, 13 Apr 2024DKK 183.5bDKK 23.9bDKK 5.0b19.4x36.4x7.7x
Mon, 11 Mar 2024DKK 193.7bDKK 23.9bDKK 5.0b19.9x38.5x8.1x
Wed, 07 Feb 2024DKK 169.6bDKK 23.3bDKK 4.2b23.2x40.8x7.3x
Fri, 05 Jan 2024DKK 175.8bDKK 23.3bDKK 4.2b25.8x42.2x7.5x
Sun, 03 Dec 2023DKK 173.8bDKK 23.3bDKK 4.2b25.2x41.8x7.5x
Tue, 31 Oct 2023DKK 158.1bDKK 22.0bDKK 4.7b18.3x33.4x7.2x
Thu, 28 Sep 2023DKK 194.3bDKK 22.0bDKK 4.7b22.9x41x8.8x
Sat, 26 Aug 2023DKK 196.4bDKK 22.0bDKK 4.7b23.3x41.6x8.9x
Mon, 24 Jul 2023DKK 211.1bDKK 19.5bDKK 4.4b41.8x47.9x10.8x
Wed, 21 Jun 2023DKK 203.1bDKK 19.5bDKK 4.4b42.7x46.1x10.4x
Fri, 19 May 2023DKK 216.2bDKK 18.6bDKK 3.8b34.8x57.5x11.6x
Sun, 16 Apr 2023DKK 212.7bDKK 17.9bDKK 3.5b33.3x60.1x11.9x
Tue, 14 Mar 2023DKK 190.0bDKK 17.9bDKK 3.5b29.5x53.6x10.6x
Price to Earnings Ratio

53.6x


Total Market Cap: DKK 190.0bTotal Earnings: DKK 3.5bTotal Revenue: DKK 17.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 30.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 10.0x which is lower than its 3-year average PE of 30.7x.
  • The 3-year average PS ratio of 6.9x is higher than the industry's current PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 62% per year over the last three years.
  • Revenues for these companies have grown 31% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-0.75%
Healthcare1.13%
Biotech-11.36%
Biotech-11.36%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BIOPOR BioPortoDKK 0.910.6%
+DKK 2.5m		-41.4%PS12.3x

Latest News

ZEAL
DKK 234.90
Zealand Pharma
7D
-35.4%
1Y
-56.0%
BAVA
DKK 182.65
Bavarian Nordic
7D
-7.5%
1Y
8.8%

BAVA: Buybacks And Latin America Vaccine Deal Will Drive Future Upside

Analysts have maintained their DKK 250 price target on Bavarian Nordic, citing only minor adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E as the reasons for this stable assessment. What's in the News CEO Paul Chaplin plans to step down for personal reasons, and the Board has agreed that he will stay in the role through the end of 2026 or until a successor is appointed.
GMAB
DKK 1,728.50
Genmab
7D
-6.5%
1Y
4.2%

GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook

Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.
BIOPOR
DKK 0.91
BioPorto
7D
0.6%
1Y
-41.4%
STRAP
DKK 580.00
Strategic Partners
7D
-7.1%
1Y
-23.7%